Literature DB >> 23105826

Non enzymatic glycosylation of IgG and their urinary excretion in patients with diabetic nephropathy.

Kinnari Mistry1, Kiran Kalia.   

Abstract

Diabetic nephropathy is a major cause of end stage renal disease. Increased excretion of albumin has widely been recognized as an early manifestation of diabetic nephropathy particularly in subjects with diabetes mellitus. However, certain other proteins besides albumin may be excreted in high amount during early phase of diabetic nephropathy. The serum and urinary IgG, Glycosylated hemoglobin, fructosamine and glycosylated IgG were evaluated in the present study. Thirty-two patients of Type 2 Diabetes without any complications, thirty-one patients of Type 2 Diabetes with nephropathy, twenty-six patients of non-diabetic nephropathy and forty normal healthy individuals were enrolled in this study. Subjects were grouped based on their serum creatinine level. Serum IgG, glycosylation of IgG and urinary IgG excretion were increased significantly in diabetic patients compared to healthy controls, which were further increased significantly in chronic renal failure patients with respect to the clinical stage of nephropathy. A positive correlation was observed between glycosylation of IgG and IgG excretion (R(2)=0.5995, 0.7114 respectively) in diabetic patients without any complications and diabetic nephropathy patients only, suggesting a significant role of IgG glycosylation in the vascular clearances of IgG during diabetic nephropathy.

Entities:  

Keywords:  Diabetic nephropathy; Fructosamine; Glycosylated hemoglobin; Glycosylation of IgG; Urinary and serum IgG

Year:  2009        PMID: 23105826      PMCID: PMC3453224          DOI: 10.1007/s12291-009-0029-7

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  34 in total

Review 1.  Advanced glycation end products: sparking the development of diabetic vascular injury.

Authors:  Alison Goldin; Joshua A Beckman; Ann Marie Schmidt; Mark A Creager
Journal:  Circulation       Date:  2006-08-08       Impact factor: 29.690

Review 2.  Glycated hemoglobin: methodologies and clinical applications.

Authors:  D E Goldstein; R R Little; H M Wiedmeyer; J D England; E M McKenzie
Journal:  Clin Chem       Date:  1986-10       Impact factor: 8.327

Review 3.  Diabetic nephropathy. An update.

Authors:  A S Reddi; R A Camerini-Davalos
Journal:  Arch Intern Med       Date:  1990-01

4.  Automated fructosamine assay with improved accuracy used to quantify nonenzymatic glycation of serum proteins in diabetes mellitus and chronic renal failure.

Authors:  S Taş; R R Zein el Din
Journal:  Clin Chem       Date:  1990-10       Impact factor: 8.327

5.  Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes.

Authors:  P H Wang; J Lau; T C Chalmers
Journal:  Lancet       Date:  1993-05-22       Impact factor: 79.321

6.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

7.  [Serum immunoglobulins and various components of complement in patients with insulin-dependent diabetes mellitus].

Authors:  Z Pietruska; I Kinalska; E Jabłońska; T Czaczkowska
Journal:  Przegl Lek       Date:  1989

8.  Blood glycated haemoglobin, serum fructosamine, serum glycated albumin and serum glycated total protein as measures of glycaemia in diabetes mellitus.

Authors:  P Koskinen; R Erkkola; J Viikari; K Mattila; K Irjala
Journal:  Scand J Clin Lab Invest       Date:  1992-12       Impact factor: 1.713

9.  Kidney disease of diabetes mellitus: NIDDK initiatives for the comprehensive study of its natural history, pathogenesis, and prevention.

Authors:  S C FitzSimmons; L Agodoa; L Striker; F Conti; G Striker
Journal:  Am J Kidney Dis       Date:  1989-01       Impact factor: 8.860

10.  Urinary transferrin excretion in type 1 (insulin-dependent) diabetes mellitus.

Authors:  M J O'Donnell; P Martin; C M Florkowski; M J Toop; C Chapman; R Holder; A H Barnett
Journal:  Diabet Med       Date:  1991 Aug-Sep       Impact factor: 4.359

View more
  7 in total

1.  Association between urinary IgG and relative risk for factors affecting proteinuria in type 2 diabetic patients.

Authors:  Sandesh Mohan; Kiran Kalia; Jyoti Mannari
Journal:  Indian J Clin Biochem       Date:  2012-06-24

2.  Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy.

Authors:  Frank A Engler; Bo Zheng; Joseph P Balthasar
Journal:  Pharm Res       Date:  2013-11-08       Impact factor: 4.200

3.  Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat.

Authors:  Gurkishan S Chadha; Marilyn E Morris
Journal:  AAPS J       Date:  2015-04-30       Impact factor: 4.009

4.  Glycosylation and Aging.

Authors:  Ana Cindrić; Jasminka Krištić; Marina Martinić Kavur; Marija Pezer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 3.650

5.  Urinary IgG, serum CX3CL1 and miRNA-152-3p: as predictors of nephropathy in Egyptian type 2 diabetic patients.

Authors:  Aml E Abdou; Haneya A A Anani; Hanan F Ibrahim; Eman Elshohat Ebrahem; Nora Seliem; Eman M I Youssef; Niveen M Ghoraba; Asmaa S Hassan; Marwa A A Ramadan; Eman Mahmoud; Shorouk Issa; Hend M Maghraby; Eman K Abdelrahman; Hala Ali Mohammed Hassan
Journal:  Tissue Barriers       Date:  2021-10-23

6.  Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients.

Authors:  Temesgen Fiseha
Journal:  Biomark Res       Date:  2015-07-04

Review 7.  An Inflammatory Story: Antibodies in Tuberculosis Comorbidities.

Authors:  Milla R McLean; Lenette L Lu; Stephen J Kent; Amy W Chung
Journal:  Front Immunol       Date:  2019-12-09       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.